Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05414409 · ClinicalTrials.gov registry record · Phase 2
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
A Phase 2 study of Obesity and Type 1 Diabetes, sponsored by Heba M. Ismail.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT05414409: Recruiting Phase 2 study of Obesity and Type 1 Diabetes, sponsored by Heba M. Ismail.
NCT05414409 is a Phase 2 study of Obesity and Type 1 Diabetes that is actively recruiting participants, run by Heba M. Ismail. The registered enrollment target is 114 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05414409, a Phase 2 study of Obesity and Type 1 Diabetes, is actively recruiting participants, sponsored by Heba M. Ismail.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Primary Outcome
cross sectional comparison of stool microbiome using metagenomic sequencing data
Conditions Studied
Interventions
- DRUG Metformin
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2026-11-02 |
| Phase | Phase 2 |
What NCT05414409 shows while recruiting
NCT05414409 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.
NCT05414409 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05414409 about?
NCT05414409 is a clinical study titled "The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action". Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight...
What is the current status of trial NCT05414409?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2022-09-30. Estimated completion is 2026-11-02.
What conditions does trial NCT05414409 study?
This clinical trial studies the following conditions: Obesity, Type 1 Diabetes.
What interventions are being tested in trial NCT05414409?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT05414409?
This trial is sponsored by Heba M. Ismail, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05414409 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05414409's enrollment target sits among peer trials
114 453rd of 1053 higher than 599 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI